SoniVie
SoniVie was an Israel-based medical device company developing the TIVUS intravascular ultrasound system for catheter-based renal denervation to treat hypertension, advancing through clinical and regulatory stages before being acquired by Boston Scientific in 2025.
- Company typePrivate
- Founded2014
- HeadquartersRosh Ha'ayin, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What SoniVie does
SoniVie Ltd. was an Israel-based (Rosh Ha'ayin) medical device company founded in 2014, focused exclusively on developing the TIVUS (Therapeutic Intravascular Ultrasound System) for ultrasound-based renal denervation as a treatment for hypertension. The company's core technology uses intravascular ultrasound energy delivered via a catheter to target the renal artery, offering a minimally invasive, non-pharmacological intervention intended to lower blood pressure in patients with hypertension, including those whose condition may be resistant to medication. SoniVie operated in a clinical and regulatory development stage, holding a registered TIVUS trademark and pursuing regulatory approval for its single core product. Its go-to-market motion was anchored on medical conferences, clinical data publication, and physician education through interventional cardiology and hypertension channels, with a future commercial distribution model intended to leverage Boston Scientific's global cardiovascular field sales network following the agreed acquisition.
The company's revenue model was structured around hardware sales of the TIVUS catheter device to hospitals and interventional cardiology providers, though it had not yet generated commercial revenue prior to acquisition. SoniVie was venture-backed, having raised a $60 million Series C in January 2023 led by Andera Partners alongside Omega Funds, Supernova Invest, and TechWald Holding, with prior capital from Accelmed and HeartX. In March 2025, Boston Scientific agreed to acquire SoniVie from Andera Partners for approximately $360 million upfront plus additional payments contingent on regulatory milestones (total deal value up to $600 million), with closing expected in the first half of 2025. Following completion, SoniVie became a wholly-owned subsidiary of Boston Scientific, and its primary customer segment transitioned to hypertension patients served through the acquiring company's established global cardiovascular sales infrastructure.
SoniVie firmographics
Firmographics- Name
- SoniVie
- Legal name
- SoniVie
- Website
- https://sonivie.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- SoniVie was an Israel-based medical device company developing the TIVUS intravascular ultrasound system for catheter-based renal denervation to treat hypertension, advancing through clinical and regulatory stages before being acquired by Boston Scientific in 2025.
- Ownership category
- akta.pro rank
SoniVie industry classification
Industry- Product category
- Renal Denervation Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)
- akta.pro secondary industry
- Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)
Keywords
Where SoniVie is headquartered
LocationHeadquarters
- HQ city
- Rosh Ha'ayin
- HQ country
- Israel
- HQ region
- Middle East
Markets served
SoniVie business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: SoniVie develops and commercializes the TIVUS ultrasound-based treatment device for hypertension. Revenue is generated through the sale of medical devices for renal denervation procedures. Prior to acquisition by Boston Scientific, the company was in clinical and regulatory development stages.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
SoniVie product offering
Product offeringCore offering
SoniVie developed the TIVUS (Therapeutic Intravascular Ultrasound System), a catheter-based ultrasound device designed to perform renal denervation by targeting the renal artery to reduce blood pressure in patients with hypertension. The company was a clinical-stage medical device developer focused on advancing the technology through regulatory milestones prior to its acquisition by Boston Scientific.
Product overview
SoniVie was a medical technology company that developed the TIVUS™ Intravascular Ultrasound System, a single core product using ultrasound technology for renal denervation to treat hypertension. The company was acquired by Boston Scientific in 2025 for approximately $360 million upfront plus additional milestone payments.
Differentiator
Problem solved
Functional benefit
Products and services
- TIVUS Intravascular Ultrasound System An intravascular ultrasound-based catheter system designed to perform renal denervation by targeting the renal artery to reduce blood pressure in patients with hypertension. Intended for use by interventional cardiologists and hypertension specialists in hospital catheterization laboratories.
Companies that use SoniVie
Customer profileSegments1 record
Ideal customer profiles1 record
SoniVie technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
SoniVie partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Boston ScientificcoreBoston Scientific agreed to acquire SoniVie from Andera Partners. The deal involves an upfront payment of approximately $360 million and additional payments upon regulatory milestones, expected to complete in the first half of 2025. This represents Boston Scientific's strategic expansion into ultrasound-based renal denervation for hypertension treatment.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
SoniVie competitors and assessment
Company assessmentDirect peers
- ReCor Medical: ReCor Medical developed the Paradise ultrasound renal denervation system, the closest direct competitor to SoniVie's TIVUS. Both companies target the same ultrasound-based RDN mechanism for hypertension and competed head-to-head in the same clinical and regulatory lanes.
Broad incumbents
- Medtronic: Medtronic commercializes the Symplicity Spyral radiofrequency renal denervation system and is the incumbent leader in RDN. It competes with TIVUS in the same resistant-hypertension category and brings significantly larger clinical evidence and commercial reach.
- Boston Scientific: Boston Scientific is SoniVie's acquirer and now its operating parent. As a broad cardiovascular medical device incumbent, it competes across hypertension and renal denervation adjacencies and provides the GTM channel SoniVie previously lacked.
Emerging players
- Ablative Solutions: Ablative Solutions developed the Peregrine System, a catheter-based perivascular renal denervation technology using a chemical ablation approach. It competes with TIVUS in the renal denervation category with a different mechanism but overlapping target indication and customers.
- Mercator MedSystems: Mercator MedSystems developed drug-coated balloon technology delivered via micro-infusion catheter, including applications in peripheral vascular disease and hypertension-adjacent indications, making it a relevant emerging player overlapping on intravascular catheter-based interventions.
- Kona Medical: Kona Medical pursued externally delivered focused ultrasound for renal denervation as a non-invasive alternative to catheter-based systems, addressing the same resistant hypertension market with a different (non-invasive) mechanism.
- Verve Medical: Verve Medical develops catheter-based systems targeting autonomic nervous system modulation to treat hypertension and related cardiovascular conditions, putting it in adjacent contention with TIVUS for the renal denervation / resistant hypertension procedure market.
Others
- Cagent Vascular: Cagent Vascular develops specialty intravascular catheter and serration-based angioplasty technology for vascular disease, sharing with SoniVie the intravascular catheter platform DNA and the same interventional cardiology/hospital procurement channels targeted by TIVUS.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
SoniVie social profiles
Digital presenceSoniVie financial estimates
Financial estimateRevenue estimate
Valuation estimate
SoniVie leadership team
Management profileNumber of profiles
SoniVie funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SoniVie M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SoniVie
What does SoniVie do?
SoniVie developed the TIVUS (Therapeutic Intravascular Ultrasound System), a catheter-based ultrasound device designed to perform renal denervation by targeting the renal artery to reduce blood pressure in patients with hypertension. The company was a clinical-stage medical device developer focused on advancing the technology through regulatory milestones prior to its acquisition by Boston Scientific.
Is SoniVie a public or private company?
SoniVie is a private company. It is classified as corporate owned and is currently acquired.
When was SoniVie founded?
SoniVie was founded in 2014. It employs 11 to 50 people.
Where is SoniVie based?
SoniVie is headquartered in Rosh Ha'ayin, Israel, in the Middle East region.
How does SoniVie make money?
One revenue line is on record: medical Device Sales.
Who are SoniVie's main competitors?
ReCor Medical is listed as a direct peer. Broad incumbents are Medtronic and Boston Scientific. Emerging players are Ablative Solutions, Mercator MedSystems, Kona Medical and Verve Medical. Cagent Vascular is listed as an others.
Does SoniVie have an API?
No public API is recorded for SoniVie.
What industry is SoniVie in?
SoniVie's product category is Renal Denervation Devices. Its primary akta.pro industry code is HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems, with a secondary code of HLAHAKAE, Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories). Its NAICS code is 334510 and its SIC code is 3841.